Therefore, our results suggest that the therapeutic targeting for Nrf2-HO-1 signaling attenuates the progression of renal fibrosis associated with diabetic nephropathy, which is manifested by the PI3K/Akt/GSK-3β pathway. This evidence concerns the gene HMOX1 and renal fibrosis.